[CAS NO. 1370032-19-1] CA-5f
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1370032-19-1]
Catalog
SLK-S5920
Brand
Selleck
CAS
1370032-19-1
DESCRIPTION [1370032-19-1]
Overview
| MDL | MFCD31813689 |
|---|---|
| Molecular Weight | 388.46 |
| Molecular Formula | C24H24N2O3 |
| SMILES | O=C(/C(CN(C)C/1)=C/C2=CNC3=CC=CC=C23)C1=C\C4=CC(OC)=C(OC)C=C4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5743 mL | 12.8713 mL | 25.7427 mL |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1485 mL |
| 10 mM | 0.2574 mL | 1.2871 mL | 2.5743 mL |
| 50 mM | 0.0515 mL | 0.2574 mL | 0.5149 mL |
Description
CA-5f is a potent late-stage inhibitor via inhibiting autophagosome-lysosome fusion.
Targets
| Autophagy [1] |
In vitro
CA-5f neither impairs the hydrolytic function nor the quantity of lysosomes. Treatment of human umbilical vein endothelial cells (HUVECs) with CA-5f for 1 h suppresses the levels of cytoskeletal proteins and membrane traffic proteins. CA-5f exhibits strong cytotoxicity against A549 non-small cell lung cancer (NSCLC) cells, but low cytotoxicity to normal human umbilical vein endothelial cells (HUVECs), by increasing mitochondrial-derived reactive oxygen species (ROS) production. CA-5f inhibits autophagic flux by blocking autophagosome-lysosome fusion instead of affecting the pH and hydrolytic function of lysosomes.
In vivo
CA-5f effectively suppresses the growth of A549 lung cancer xenograft as a single agent with an excellent tolerance in vivo. It inhibits autophagic flux, induced apoptosis, and does not affect the level of CTSB (cathepsin B) and CTSD (cathepsin D) in vivo.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.